Compound Report Overview
Compound Name:
LYSERGOL
Compound Identifier:
701000
Mol Structure 2D:
701000
Molecular Weight:
254
Formula:
C16 H18 N2 O
Development Status:
Toxicology standard
SMILES:
CN1CC(CO)C=C2C1Cc3c[nH]c4cccc2c34
Compound Activites
| Compound | Assay | Assay Name | View |
|---|---|---|---|
| LYSERGOL | 205 | Serotonin 5-HT2B | View |
| LYSERGOL | 637 | Serotonin 5-HT1B | View |
| LYSERGOL | 206 | Serotonin 5-HT2C | View |
| LYSERGOL | 84 | Adrenergic alpha2A | View |
| LYSERGOL | 114 | Dopamine D2L | View |
| LYSERGOL | 200 | Serotonin 5-HT1A | View |
| LYSERGOL | 113 | Dopamine D1 | View |
| LYSERGOL | 82 | Adrenergic alpha1D | View |
| LYSERGOL | 81 | Adrenergic alpha1B | View |
| LYSERGOL | 89 | Adrenergic beta2 | View |
| LYSERGOL | 88 | Adrenergic beta1 | View |
| LYSERGOL | 213 | Sigma1 | View |
| LYSERGOL | 640 | CYP450-1A2 Inhibition | View |
| LYSERGOL | 103 | Calcium Channel Type L, Phenylalkylamine | View |
| LYSERGOL | 148 | Histamine H2 | View |
| LYSERGOL | 183 | Opiate mu | View |
| LYSERGOL | 641 | CYP450-2C19 Inhibition | View |
| LYSERGOL | 643 | CYP450-2D6 Inhibition | View |
| LYSERGOL | 151 | Imidazoline I2, Central | View |
| LYSERGOL | 86 | Adrenergic alpha2C | View |
| LYSERGOL | 80 | Adrenergic alpha1A | View |
| LYSERGOL | 85 | Adrenergic alpha2B | View |
| LYSERGOL | 204 | Serotonin 5-HT2A | View |
| LYSERGOL | 116 | Dopamine D3 | View |
| LYSERGOL | 210 | Serotonin 5-HT6 | View |
| LYSERGOL | 629 | Protease, Matrix Metalloprotease-1 (MMP-1) | View |
| LYSERGOL | 90 | Adrenergic beta3 | View |